EUCTR2016-005187-34-GB进行中（未招募）1 期
Stereotactic body radiotherapy with immunotherapy in early stage non-small cell lung cancer: tolerability and lung effects - STILE version 1.0
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Subjects must have signed and dated an Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care
- •- Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory tests
- •- ECOG Performance status (PS) 0-2
- •- Minimum of first 5 patients to be PS 0-1
- •- PS 2 patients to be enrolled only following approval by the Independent Data Monitoring Committee (IDMC)
- •- Patients with histological diagnosis of NSCLC, all histological sub-types are eligible
- •- Tumour stage T1-3 (=5cm), N0 M0 (UICC v.7) as determined by the local MDT based on minimum investigations of CT performed within 8 weeks of 1st dose of SBRT and FDG-PET performed within 6 weeks of 1st dose of SBRT. Where the radiological nodal status is equivocal then only eligible if possible nodal disease is subsequently confirmed as pathologically negative with mediastinoscopy or endoscopic bronchial or oesophageal ultra-sound biopsy as necessary
- •- Not suitable for surgery because of medical co-morbidity, lesion is technically inoperable or patient declines surgery after surgical assessment (or option of assessment)
- •- Peripheral lesions i.e. outside a 2cm radius of main airways and proximal bronchial tree. This is defined as 2cm from the bifurcation of the second order bronchus e.g. where the right upper lobe bronchus splits (See Appendix 4)
- •- Screening laboratory values must meet the following criteria prior to commencement of treatment:
- •i) WBCs = 2000/µL
- •ii) Neutrophils =1500/µL
- •iii) Platelets = 100 X10³/µL
- •iv) Haemoglobin = 9.0 g/dL
- •v) Serum creatinine of = 1.5 X ULN or creatinine clearance (CrCl)/glomerular filtration rate (GFR) > 40 mL/minute (using Cockcroft/Gault formula or as assessed by local practice)
- •(1). Female CrCl= [(140- age in years) X weight in kg X 0.85) ÷ (72 X serum creatinine in mg/ dL)]
- •(2). Male CrCl= [(140- age in years) X weight in kg X 1.00) ÷ (72 X serum creatinine in mg/ dL)]
- •vi) AST = 3 X ULN
- •vii) ALT = 3 X ULN
- •viii) Total bilirubin = 1.5 X ULN (except subjects with Gilbert Syndrome, who must have total bilirubin < 50micrml/L)
- •- No prior adjuvant or foreseen neo-adjuvant or adjuvant chemotherapy is allowed
- •- Males and Females = 18 years of age
- •- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.
- •- Women must not be breastfeeding during the study treatment and for a period up to 23 weeks post treatment completion (See Appendix 1)
- •- WOCBP must agree to follow instructions for method(s) of contraception during the study treatment and for a total of 23 weeks post treatment completion (See Appendix 1)
- •- Males who are sexually active with WOCBP must agree to follow instructions for method(s) for contraception for a total of 31 weeks post treatment completion
排除标准
- •- Any tumour that is not clinically definable on the treatment planning CT scan e.g. surrounded by consolidation or atelectasis
- •- Subjects with active, known autoimmune disease. Subjects with Type I diabetes mellitus, residual hypothyroidism due to an autoimmune condition requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol.
- •- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of the first dose of study drug administration. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease
- •- Subjects with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
- •- Patient with known interstitial lung disease or active, non-infectious pneumonitis
- •- Previous radiotherapy to the chest or mediastinum. Patients who have had previous breast radiotherapy may be eligible at the discretion of the principal investigator
- •- Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the subject to receive protocol therapy
- •- All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to Grade 1 (NCI CTCAE v.4.0) or baseline before administration of study drug
- •- Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment
- •- Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) or who have previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab
- •- Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- •- Positive test for hepatitis B virus (HBV) using HBV surface antigen (HBVsAg) test or positive test for hepatitis C virus (HCV) using HCV ribonucleic acid (RNA) or HCV antibody test indicating acute or chronic infection
- •- Patients with a positive HCV antibody but no detection of HCV RNA indicating no current infection are eligible
- •- Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment
- •- History of allergy to study drug components
研究者
相似试验
已完成
2 期
Stereotactic body radiotherapy followed by surgical stabilization for patients with painful unstable spinal metastases: First-in-man study according to the IDEAL recommendationsmetastatic spine tumorspinal metastases100059591002747610005944NL-OMON42087niversitair Medisch Centrum Utrecht13
招募中
不适用
Stereotactic Body Radiotherapy for the Management of Prostate Cancer Local RecurrencesC61Malignant neoplasm of prostateDRKS00030837Europäisches Radiochirurgie Centrum München50
招募中
不适用
Potential abscopal effect of stereotactic body radiotherapy on the recurrence of hepatocellular carcinoma: An exploratory observation studyHepatocellular carcinomaJPRN-UMIN000038312ational Hospital Organization Nagasaki Medical Center280
招募中
不适用
Dose-optimized stereotactic body radiotherapy for locally advanced or recurrent pancreatic andenocarcinomaC25Malignant neoplasm of pancreasDRKS00027912ordstrahl30
进行中（未招募）
1 期
Addition of stereotactic body radiotherapy (SBRT) to chemotherapy in locally advanced biliary tract cancersocally advanced biliary tract cancerMedDRA version: 21.0Level: LLTClassification code 10004586Term: Bile duct adenocarcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864EUCTR2014-003656-31-GBniversity College London81